API-1 (Synonyms: NSC 177223) |
カタログ番号GC18374 |
強力な Akt/PKB 阻害剤である API-1 は、PH ドメインに結合し、Akt 膜移行を阻害します。 API-1 は、約 0.8 μM の IC50 で Akt のリン酸化レベルを効率的に低下させます。 API-1 は PKB に対して選択的であり、PKC および PKA の活性化を阻害しません。 API-1 は、TNF 関連アポトーシス誘導リガンド (TRAIL) との相乗効果によってアポトーシスも誘導します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 36707-00-3
Sample solution is provided at 25 µL, 10mM.
API-1 is an inhibitor of Akt that reduces the level of phosphorylated Akt (IC50 = ~0.8 uM in OVCAR3 cells) by binding to Akt and blocking its translocation to the cell membrane. It reduces cell proliferation in various cancer cell lines, induces apoptosis, and, at a dose of 10 mg/kg per day, decreases tumor growth in a mouse xenograft model. API-1 inhibition of Akt leads to proteasomal degradation of the downstream mediator Mcl-1. Likely independent of Akt binding, API-1 inhibits cell growth (IC50s = 2-5 uM) and induces apoptosis in non-small cell lung and head and neck squamous cancer (NSCLC and HNSCC) cell lines with concomitant increases in caspase-3, -8, and -9 cleavage. It reduces the levels of cellular FLICE-inhibitory protein (c-FLIP), an important regulator of apoptosis, through ubiquitin- and proteasome-mediated degradation. It also has a synergistic effect on apoptosis in combination with TRAIL/APO-2L.The information regarding the reduction in phosphorylated Akt levels, IC50 value, translocation, cell proliferation, and xenograft tumor growth was drawn from a paper that has been retracted; however, the information specified in the retraction statement has not been included.
Review for API-1
Average Rating: 5
(Based on Reviews and 6 reference(s) in Google Scholar.)Review for API-1
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *